Form 8-K - Current report:
SEC Accession No. 0001628280-25-059155
Filing Date
2025-12-31
Accepted
2025-12-30 18:45:43
Documents
14
Period of Report
2025-12-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20251230.htm   iXBRL 8-K 30388
2 EX-99.1 vnda8-k12302025exhibit991.htm EX-99.1 26317
6 vandaq32019earningsca_imaga.jpg GRAPHIC 49643
  Complete submission text file 0001628280-25-059155.txt   251945

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20251230.xsd EX-101.SCH 1834
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20251230_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20251230_pre.xml EX-101.PRE 13084
16 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20251230_htm.xml XML 2834
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 251615435
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)